Workflow
Immunocore(IMCR)
icon
Search documents
New Strong Buy Stocks for December 12th
ZACKS· 2024-12-12 12:21
Stocks Added to Zacks Rank 1 (Strong Buy) List - NB Bancorp Inc (NBBK): The bank holding company for Needham Bank has seen an 11% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Omnicell Inc (OMCL): The medication management solutions provider has experienced a 20% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - ZIM Integrated Shipping Services Ltd (ZIM): The container shipping provider has seen a 35.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Immunocore Holdings plc (IMCR): The biotechnology company has experienced a 47.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - UL Solutions Inc (ULS): The safety science services provider has seen a 7.4% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3]
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
GlobeNewswire News Room· 2024-12-03 06:00
KIMMTRAK Reimbursement Agreement - KIMMTRAK (tebentafusp) has been recommended for funding through the NHS in England by NICE for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma [1] - This recommendation overturns the initial negative decision by NICE in May 2023, which the company successfully appealed in December 2023 [2] - KIMMTRAK is now funded on the NHS in England as of 02 December 2024 [4] Impact on Patients and Medical Community - KIMMTRAK is the first therapy to improve survival for HLA-A*02:01-positive metastatic or unresectable uveal melanoma, marking a major step forward for patients and their families [3] - Uveal melanoma is a very rare form of melanoma requiring different clinical management, and the option to prescribe tebentafusp represents a significant advancement for patients [3] - The recommendation highlights the power of collaboration between patients, advocates, and medical experts in advancing care for ocular melanoma [4] About KIMMTRAK and Uveal Melanoma - KIMMTRAK is a novel bispecific protein targeting gp100, a lineage antigen expressed in melanocytes and melanoma, developed using Immunocore's ImmTAC technology platform [6] - Uveal melanoma is a rare and aggressive form of melanoma affecting the eye, with up to 50% of patients developing metastatic disease and historically having no approved treatment until KIMMTRAK [5] - KIMMTRAK is indicated as monotherapy for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in multiple regions, including the US, EU, Canada, Australia, and the UK [7] Immunocore's Technology and Pipeline - Immunocore's proprietary TCR technology generates ImmTAC molecules, designed to redirect the immune system to recognize and kill cancerous cells, with potential applications in hematologic and solid tumors [9] - The company is a commercial-stage biotechnology firm pioneering the development of TCR bispecific immunotherapies (ImmTAX) for cancer, autoimmune diseases, and infectious diseases [10] - Immunocore has nine active clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases, with KIMMTRAK being its most advanced oncology TCR therapeutic [10]
Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect?
ZACKS· 2024-11-28 16:01
Stock Performance and Price Targets - Shares of Immunocore Holdings PLC Sponsored ADR (IMCR) gained 2 9% over the past four weeks closing at $32 83 with a potential upside of 112 8% based on the mean price target of $69 87 [1] - The mean estimate includes 15 short-term price targets with a standard deviation of $21 22 indicating variability among analysts The lowest estimate is $24 (26 9% decline) while the most optimistic target is $100 (204 6% surge) [2] - A low standard deviation suggests greater agreement among analysts which could be a good starting point for further research [7] Analysts' Price Targets and Earnings Estimates - Analysts' growing optimism over IMCR's earnings prospects is supported by strong agreement in revising EPS estimates higher which historically correlates with near-term stock price movements [9] - The Zacks Consensus Estimate for the current year increased by 44% over the past month with eight positive revisions and no negative revisions [10] - IMCR holds a Zacks Rank 1 (Strong Buy) placing it in the top 5% of over 4 000 stocks based on earnings estimate factors indicating strong potential upside [11] Limitations of Price Targets - Price targets can mislead investors as empirical research shows they rarely predict actual stock price movements accurately [5] - Analysts may set overly optimistic price targets to generate interest in stocks often influenced by business incentives rather than unbiased analysis [6] - Investors should not rely solely on price targets for investment decisions as they should be treated with skepticism [8]
New Strong Buy Stocks for November 26th
ZACKS· 2024-11-26 12:26
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:ZIM Integrated Shipping Services Ltd. (ZIM) : This container shipping provider has seen the Zacks Consensus Estimate for its current year earnings increasing 41.7% over the last 60 days.monday.com Ltd. (MNDY) : This software development company has seen the Zacks Consensus Estimate for its current year earnings increasing 15.9% over the last 60 days.Rush Street Interactive, Inc. (RSI) : This online casino and sports betting company has ...
Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know
ZACKS· 2024-11-08 15:55
Immunocore Holdings PLC Sponsored ADR (IMCR) closed the last trading session at $34.31, gaining 11.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $72.93 indicates an 112.6% upside potential.The average comprises 15 short-term price targets ranging from a low of $24 to a high of $100, with a standard deviation of $18.74. While the lowest estimate indicates a decline of 30.1% fro ...
Immunocore(IMCR) - 2024 Q3 - Quarterly Results
2024-11-06 12:22
Exhibit 99.1 Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cutaneous melanoma ongoing (PRISM-MEL-301 and TEBE-AM); and Phase 3 trial in adjuvant uveal melanoma (ATOM) to start randomizing in 4Q 2024 Presented Phase 1 brenetafusp data in platinum-resistant ovarian cancer patients; ongoing signal detection in metastatic NSCLC will shift initial data release; focu ...
Immunocore(IMCR) - 2024 Q3 - Quarterly Report
2024-11-06 12:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-39992 Immunocore Holdings plc (Exact name of registrant as specified in its charter) | --- | --- | |-------- ...
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
GlobeNewswire News Room· 2024-09-14 07:00
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically active as monotherapy and in combination with chemotherapy in heavily pretreated, platinum-resistant ovarian cancer patients T cell fitness gene expression signature in blood is an important parameter of clinical activity for tebentafusp in uveal melanoma and for brenetafusp across different tumor types (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., ...
Immunocore: Pipeline Expands HLA Tumor Targeting Beyond Kimmtrak
Seeking Alpha· 2024-08-30 15:40
Bevan Goldswain/E+ via Getty Images Immunocore (NASDAQ:IMCR) has made significant progress in being able to use its proprietary ImmTAX platform to develop T-cell receptors [TCRs] against a variety of types of cancer. It has already received FDA approval of Kimmtrak for the treatment of patients with advanced or metastatic uveal melanoma who are HLAA*02:01-positive. Sales for this drug franchise continue to climb, especially when you consider the reported number. It was stated that in Q2 of 2024, sales of Ki ...
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
Newsfilter· 2024-06-18 11:00
First registrational Phase 3 trial investigating PRAME-targeted therapy "We are very proud to have started the registrational program for brenetafusp, our PRAME candidate, supported by the recent promising brenetafusp monotherapy data in late-line cutaneous melanoma" said Mohammed Dar, Senior Vice President, Clinical Development, and Chief Medical Officer, Immunocore. "The PRISM-MEL301 trial – the first Phase 3 trial for any PRAME-targeted therapy – will test whether combining brenetafusp with nivolumab may ...